ArticleGates open research2026
Zero-Dose Childhood Immunization in Conflict-Affected PSNP Districts of Ethiopia: A Comparative Cross-Sectional Study.
Article in Gates open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors Associated with Childhood Vaccination in Sub-Saharan African Countries Experiencing Armed Conflicts: A Scoping Review.Journal of epidemiology and global health · 2026Article
- Factors contributing to low uptake of vaccination in underserved communities: a mixed-method diagnostic design in Southwest Region of Cameroon.The Pan African medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood immunisation is one of the most cost-effective public health interventions, preventing 4-5 million deaths annually. This study assessed the prevalence and determinants of zero-dose immunisation among children aged 12-35 months in conflict-affected districts implementing Ethiopia's Productive Safety Net Programme (PSNP) to determine whether intervention and comparison areas are comparable before rollout of the enhanced service-integration model. Methods: A comparative cross-sectional survey was conducted among 4,099 mothers and caregivers of children aged 12-35 months in intervention and comparison PSNP districts. Data were collected using a structured questionnaire administered by trained enumerators. Multivariable logistic regression was used to identify factors associated with zero-dose status. Results: Zero-dose prevalence was 30% in intervention districts and 27% in comparison districts, with notable regional disparities: 22.5% in Amhara, 23% in Afar, and 39% in Tigray. Vaccination dropout showed a different pattern, with the highest rate in Afar (57.6%) and the lowest in Tigray (13.6%). DTP3 coverage was lowest in Afar (42.9%) and highest in Amhara (69.4%), while MCV1 coverage was highest in Tigray (83.8%), followed by Amhara (79.6%) and Afar (49.1%). In intervention districts, zero-dose status was significantly associated with region (AOR = 1.5; 95% CI: 1.1-2.2), lack of maternal education (AOR = 1.7; 95% CI: 1.1-2.7), unmarried status (AOR = 1.8; 95% CI: 1.0-3.2), older child age (24-35 months) (AOR = 3.7; 95% CI: 2.6-5.3), and longer distance to health facilities (AOR = 1.4; 95% CI: 1.0-2.2). In comparison districts, region, maternal education, and older child age remained significant predictors. Conclusions: The study highlights persistent inequities in immunisation coverage in conflict-affected settings. It also demonstrates comparability between intervention and comparison PSNP districts in zero-dose prevalence and its determinants. These baseline findings provide a foundation for attributing future post-intervention improvements to enhanced integration of health services within the PSNP framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.